Pharmaceutical Industry discussion, review, analysis, news and information. |
« Serono Earmarks $10 Billion in Acquisitions | Main | Gentope Corp.’s MyVax® Personalized Immunotherapy Phase 3 Trial, Recommended to Proceed by DSMB »
|
Jul30
|
 "...The market is estimated to be in excess of £15m within the EU. However, treatment of xerostomia as a side-effect of drug treatment is understated, and BioProgress believes that this market offers good potential for growth. We anticipate that HypoSalix could achieve significant market share." HypoSalix will be launched in the next six months in several EU markets by Dexo BioPharm. Source: Bioprogress |
TrackBack URL for this entry:
« Serono Earmarks $10 Billion in Acquisitions | Main | Gentope Corp.’s MyVax® Personalized Immunotherapy Phase 3 Trial, Recommended to Proceed by DSMB »
Use these fast growing business social media sites to promote your business, feature your products, spotlight your business leaders, create links, and drive traffic back to your company site, all for free!
BIZZlogos - Add your logo - free link to your site| View Network Map Network Feed List (OPML) Know More Media Network Feed |
PharmaGazette is a member of the Know More Media network of business related blogs.
Here are some current headlines from some of our business publications:
ProductivityGoal | CallCenterScript |
AdHurl | TheBizofKnowledge |
LandingTheDeal | CustomersAreAlways |
HealthCareVox | BrainBasedBusiness |
TheInsurancePolicy | MarketingBlurb |
Write for us About us Contact Advertise Privacy Disclaimer
This weblog is licensed under a Creative Commons License.
Comment Preview